IGFBP2 and glioblastoma: The identified MRs, particularly insulin-like growth factor binding protein 2 (IGFBP2), vascular endothelial growth factor A (VEGFA), VEGF165, platelet-derived growth factor A (PDGFA), adipocyte enhancer-binding protein (AEBP1), and oncostatin M (OSMR), were proposed as biomarkers and therapeutic targets for enhancing GBM prognosis [36].